FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2776100072> ?p ?o ?g. }

• W2776100072 endingPage "5651" @default.
• W2776100072 startingPage "5641" @default.
• W2776100072 abstract "// Anne Oberson 1, * , Lorenzo Spagnuolo 1, 2, 3, * , Viola Puddinu 2, 3 , Winfried Barchet 4, 5 , Karola Rittner 6 and Carole Bourquin 1, 2, 3 1 Chair of Pharmacology, Department of Medicine, Faculty of Science, University of Fribourg, 1700 Fribourg, Switzerland 2 School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneva, Switzerland 3 Department of Anesthesiology, Pharmacology and Intensive Care, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland 4 German Center for Infection Research, Cologne-Bonn, Germany 5 Institute for Clinical Chemistry and Clinical Pharmacology, University of Bonn, Germany 6 Transgene S.A., Parc d’Innovation, CS80166, 67405 Illkirch-Graffenstaden Cedex, France * These authors contributed equally to this work Correspondence to: Carole Bourquin, email: carole.bourquin@unige.ch Keywords: poly(I:C); NAB2; pattern-recognition receptors; interferon; cancer immunotherapy Received: April 13, 2017      Accepted: October 13, 2017      Published: December 15, 2017 ABSTRACT Novel adjuvants are needed to increase the efficacy of vaccine formulations and immune therapies for cancer and chronic infections. In particular, adjuvants that promote a strong type I IFN response are required, since this cytokine is crucial for the development of efficient anti-tumoral and anti-viral immunity. Nucleic acid band 2 (NAB2) is a double-stranded RNA molecule isolated from yeast and identified as an agonist of the pattern-recognition receptors TLR3 and MDA-5. We compared the ability of NAB2 to activate innate immunity with that of poly(I:C), a well-characterized TLR3 and MDA-5 agonist known for the induction of type I IFN. NAB2 promoted stronger IFN-α production and induced a higher activation state of both murine and human innate immune cells compared to poly(I:C). This correlated with a stronger activation of the signalling pathway downstream of MDA-5, and IFN-α induction was dependent on MDA-5. Upon injection, NAB2 induced higher levels of serum IFN-α in mice than poly(I:C). These results suggest that NAB2 has the potential to become an efficient adjuvant for the induction of type-I IFN responses in therapeutic immunization against cancer or infections." @default.
• W2776100072 created "2018-01-05" @default.
• W2776100072 creator A5022369311 @default.
• W2776100072 creator A5046608830 @default.
• W2776100072 creator A5047754584 @default.
• W2776100072 creator A5063348136 @default.
• W2776100072 creator A5066332743 @default.
• W2776100072 creator A5084753559 @default.
• W2776100072 date "2017-12-15" @default.
• W2776100072 modified "2023-10-17" @default.
• W2776100072 title "NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response" @default.
• W2776100072 cites W1176162522 @default.
• W2776100072 cites W1542820960 @default.
• W2776100072 cites W1801998969 @default.
• W2776100072 cites W1894719160 @default.
• W2776100072 cites W1964271390 @default.
• W2776100072 cites W1966233007 @default.
• W2776100072 cites W1972784345 @default.
• W2776100072 cites W1974895889 @default.
• W2776100072 cites W1976209243 @default.
• W2776100072 cites W1992088744 @default.
• W2776100072 cites W1995744610 @default.
• W2776100072 cites W1997117545 @default.
• W2776100072 cites W1997491414 @default.
• W2776100072 cites W1999144941 @default.
• W2776100072 cites W2006821600 @default.
• W2776100072 cites W2013326148 @default.
• W2776100072 cites W2014674377 @default.
• W2776100072 cites W2021021710 @default.
• W2776100072 cites W2042433863 @default.
• W2776100072 cites W2047365750 @default.
• W2776100072 cites W2052845121 @default.
• W2776100072 cites W2065554630 @default.
• W2776100072 cites W2071670416 @default.
• W2776100072 cites W2073034575 @default.
• W2776100072 cites W2076361525 @default.
• W2776100072 cites W2084880831 @default.
• W2776100072 cites W2097556922 @default.
• W2776100072 cites W2100262165 @default.
• W2776100072 cites W2102953855 @default.
• W2776100072 cites W2106248075 @default.
• W2776100072 cites W2117342688 @default.
• W2776100072 cites W2121599485 @default.
• W2776100072 cites W2131981794 @default.
• W2776100072 cites W2137303998 @default.
• W2776100072 cites W2138408665 @default.
• W2776100072 cites W2143523733 @default.
• W2776100072 cites W2148201382 @default.
• W2776100072 cites W2156313733 @default.
• W2776100072 cites W2218377234 @default.
• W2776100072 cites W2402613250 @default.
• W2776100072 cites W2512397510 @default.
• W2776100072 cites W2517416985 @default.
• W2776100072 cites W2562954116 @default.
• W2776100072 doi "https://doi.org/10.18632/oncotarget.23725" @default.
• W2776100072 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5814164" @default.
• W2776100072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29464024" @default.
• W2776100072 hasPublicationYear "2017" @default.
• W2776100072 type Work @default.
• W2776100072 sameAs 2776100072 @default.
• W2776100072 citedByCount "6" @default.
• W2776100072 countsByYear W27761000722019 @default.
• W2776100072 countsByYear W27761000722020 @default.
• W2776100072 countsByYear W27761000722021 @default.
• W2776100072 crossrefType "journal-article" @default.
• W2776100072 hasAuthorship W2776100072A5022369311 @default.
• W2776100072 hasAuthorship W2776100072A5046608830 @default.
• W2776100072 hasAuthorship W2776100072A5047754584 @default.
• W2776100072 hasAuthorship W2776100072A5063348136 @default.
• W2776100072 hasAuthorship W2776100072A5066332743 @default.
• W2776100072 hasAuthorship W2776100072A5084753559 @default.
• W2776100072 hasBestOaLocation W27761000721 @default.
• W2776100072 hasConcept C126322002 @default.
• W2776100072 hasConcept C203014093 @default.
• W2776100072 hasConcept C2777701055 @default.
• W2776100072 hasConcept C71924100 @default.
• W2776100072 hasConcept C8891405 @default.
• W2776100072 hasConcept C98274493 @default.
• W2776100072 hasConceptScore W2776100072C126322002 @default.
• W2776100072 hasConceptScore W2776100072C203014093 @default.
• W2776100072 hasConceptScore W2776100072C2777701055 @default.
• W2776100072 hasConceptScore W2776100072C71924100 @default.
• W2776100072 hasConceptScore W2776100072C8891405 @default.
• W2776100072 hasConceptScore W2776100072C98274493 @default.
• W2776100072 hasIssue "5" @default.
• W2776100072 hasLocation W27761000721 @default.
• W2776100072 hasLocation W27761000722 @default.
• W2776100072 hasLocation W27761000723 @default.
• W2776100072 hasLocation W27761000724 @default.
• W2776100072 hasLocation W27761000725 @default.
• W2776100072 hasLocation W27761000726 @default.
• W2776100072 hasOpenAccess W2776100072 @default.
• W2776100072 hasPrimaryLocation W27761000721 @default.
• W2776100072 hasRelatedWork W157270364 @default.
• W2776100072 hasRelatedWork W1996150995 @default.
• W2776100072 hasRelatedWork W2023771859 @default.
• W2776100072 hasRelatedWork W2107710620 @default.
• W2776100072 hasRelatedWork W2380021556 @default.

• next